10-Q: Zoetis Inc. Reports 1% Revenue Increase in Q1 2025, Driven by Companion Animal Growth

Sentiment:

Quarterly Report 6 May 2025 1:29 PM

Zoetis Inc. announces a 1% increase in revenue for the first quarter of 2025, with growth primarily driven by the companion animal sector, while navigating foreign exchange headwinds and the impact of a recent divestiture.

Summary

Zoetis Inc. reported a 1% increase in revenue for Q1 2025, reaching $2,220 million compared to $2,190 million in Q1 2024.
On an operational basis, revenue increased by 5%, driven by price and volume growth, but offset by a 4% decrease due to the divestiture of the medicated feed additive product portfolio.
Net income attributable to Zoetis increased by 5% to $631 million, or $1.41 per diluted share, compared to $599 million, or $1.31 per diluted share, in the prior year.
The U.S. segment saw a 2% revenue increase, driven by companion animal products, while the international segment remained flat but experienced a 7% operational revenue increase.
The company's effective tax rate increased to 22.1% from 19.8% due to higher net discrete tax expenses and a less favorable jurisdictional mix of earnings.
Zoetis repurchased 2.7 million shares for $443 million during the quarter, with $5.2 billion remaining under the share repurchase program.
The company reaffirms its belief that its cash and cash equivalents, operating cash flows, and existing financing arrangements will be sufficient to support its cash needs for the next twelve months and beyond.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with revenue and income growth, but also acknowledges challenges such as foreign exchange impacts and divestiture effects. The company's strong financial position and share repurchase program contribute to a favorable sentiment.

Positives

Companion animal revenue growth in both the U.S. and international segments drove overall revenue increase.
Operational revenue growth of 5% indicates strong underlying business performance.
The company remains in compliance with all financial covenants related to its credit facility.
Zoetis has a strong cash position and access to credit facilities, ensuring sufficient liquidity.
Gross margin in the U.S. segment increased from 81.3% to 83.2%.

Negatives

Foreign exchange rates negatively impacted revenue growth by approximately 4%.
The divestiture of the medicated feed additive product portfolio reduced revenue by 4%.
Livestock revenue in the U.S. declined by 21% due to the impact of the MFA divestiture.
The effective tax rate increased from 19.8% to 22.1%.

Risks

The company faces risks related to tariffs and trade protection measures, which could increase costs and disrupt supply chains.
Outbreaks of animal diseases could adversely affect sales of livestock products.
Fluctuations in foreign exchange rates could impact revenue and profitability.
The company relies on third parties for products, materials, and services, making it vulnerable to supply disruptions and increased costs.
Zoetis is subject to substantial regulation, and failure to comply could result in penalties and restrictions.

Future Outlook

The company believes its cash and cash equivalents, operating cash flows, and existing financing arrangements will be sufficient to support its cash needs for the next twelve months and beyond, subject to the operating environment.

Management Comments

Management measures performance using non-GAAP financial measures that may exclude certain amounts from the most directly comparable GAAP measure.
Management believes that it is important to not only understand overall revenue and earnings results, but also operational results.
Management believes these financial measures are useful supplemental information to investors when considered together with our U.S. GAAP financial measures.

Industry Context

Zoetis operates in the global animal health industry, competing with other companies in the development, manufacture, and commercialization of medicines, vaccines, and diagnostic products. The growth in the companion animal sector is driven by economic development, increased disposable income, and rising pet ownership. The livestock sector is influenced by human population growth, increasing standards of living, and a focus on food quality and safety.

Comparison to Industry Standards

The document does not provide specific comparisons to industry standards or benchmarks.
Without additional information, it's difficult to assess Zoetis's performance relative to competitors like Elanco, Merck Animal Health, or Boehringer Ingelheim Animal Health.
A comprehensive industry analysis would require comparing Zoetis's growth rates, profitability margins, and R&D investments against those of its peers.

Legal Proceedings

The company is currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018.
In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return.
In September 2024, the IRS issued a Revenue Agent Report (RAR) for the adjustments identified in the NOPA and a protest was filed with the IRS on November 15, 2024.
As of March 31, 2025, the additional tax liability, based on the income adjustment proposed by the IRS under the RAR, is approximately $450 million, excluding interest and penalties.
The company is involved in legal proceedings related to Ulianopolis, Brazil, concerning alleged environmental impacts from waste disposal.

Stakeholder Impact

Shareholders: The share repurchase program and dividend payments benefit shareholders.
Employees: Share-based compensation plans provide long-term incentives to employees.
Customers: The company's focus on innovation and product development aims to meet customer needs.
Suppliers: The company's reliance on third-party suppliers creates interdependencies.
Creditors: The company's compliance with financial covenants ensures its ability to meet debt obligations.

Next Steps

The company will continue to monitor the mix of U.S. and international cash flows.
Zoetis will continue to actively monitor the situation and evaluate actions that can be taken to moderate and/or minimize the effects of tariffs and trade protection measures.
The company will continue to evaluate the adequacy of our tax reserve as the audit progresses.

Key Dates

Date	Description
2012-02-29	Date of Ulianopolis, Brazil incident
2012-04-01	Date of Ulianopolis, Brazil incident
2013-02	Zoetis entered into a commercial paper program with a capacity of up to $1.0 billion.
2015-03-05	Zoetis presented its response to the prosecutors proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter.
2015-05-29	Zoetis, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic.
2016-08-19	The parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site.
2017-06	The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017.
2017-11	A written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017.
2019-04-01	The defendants met with the Prosecutor to discuss the conclusions set forth in the written report.
2019-04-10	The Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments.
2019-08	Acquisition of Platinum Performance business
2019-10-21	The defendants presented the technical proposal to the Prosecutor.
2020-03-03	The Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor.
2020-07-15	The Prosecutor recommended certain amendments to the proposal for the Phase II testing.
2020-09-28	The parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing.
2020-10-14	Phase II testing began the week of October 14, 2024.
2020-12	Zoetis submitted a final voluntary disclosure to OFAC and the U.S. Department of Justice regarding certain transactions involving sales of food, medicine or devices to individuals or entities who may have been resident in or had ties to Iran potentially in violation of the ITSR administered by OFAC.
2022-05-19	Zoetis 2013 Equity and Incentive Plan, Amended and Restated as of May 19, 2022 (Equity Plan), provides long-term incentives to our employees and non-employee directors.
2022-12	Zoetis entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027.
2023-07	OFAC provided a No Action letter confirming a final determination that no further action would be taken in the matter.
2023-12	The FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax disclosures.
2024-07	The IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return.
2024-08	Our Board of Directors authorized a multi-year share repurchase program of up to $6 billion of our outstanding common stock.
2024-09	The IRS issued a Revenue Agent Report (RAR) for the adjustments identified in the NOPA and a protest was filed with the IRS on November 15, 2024.
2024-10-31	Zoetis completed the divestiture of its medicated feed additive product portfolio, certain water soluble products and related assets to Phibro Animal Health for an estimated net purchase price of $309 million.
2024-11	The FASB issued ASU No. 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.
2024-11-15	A protest was filed with the IRS on November 15, 2024.
2025-01-01	We adopted this guidance as of January 1, 2025, which will result in additional disclosures in the notes to our annual consolidated financial statements.
2025-03-31	End of the quarterly period.
2025-05-02	As of May 2, 2025, there were 445,208,053 shares of common stock outstanding.
2025-05-06	Date of report.
2026-03	Forward-starting interest rate swaps, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500% 2015 senior notes due 2025.
2027-12	The credit facility expires in December 2027.

Keywords

Zoetis, revenue, animal health, companion animal, livestock, financial results, Q1 2025, earnings, share repurchase, financial statements

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.